Therapeutic Effectiveness of Interferon-α2b against COVID-19 with Community-Acquired Pneumonia: The Ukrainian Experience

Despite several targeted antiviral drugs against SARS-CoV-2 currently being available, the application of type I interferons (IFNs) still deserves attention as an alternative antiviral strategy. This study aimed to assess the therapeutic effectiveness of IFN-α in hospitalized patients with COVID-19-...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-04, Vol.24 (8), p.6887
Main Authors: Kamyshnyi, Aleksandr, Koval, Halyna, Kobevko, Olha, Buchynskyi, Mykhailo, Oksenych, Valentyn, Kainov, Denis, Lyubomirskaya, Katerina, Kamyshna, Iryna, Potters, Geert, Moshynets, Olena
Format: Article
Language:English
Subjects:
Adult
Antiviral Agents - therapeutic use
Biological response modifiers
Coronaviruses
COVID-19
CT-diagnosed lung injuries
Health aspects
hospital stay
Humans
IFN-α2b
Interferon alpha-2 - therapeutic use
Interferon-alpha - therapeutic use
Prospective Studies
SARS-CoV-2
Severe acute respiratory syndrome
SpO2
therapeutic effectiveness
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite several targeted antiviral drugs against SARS-CoV-2 currently being available, the application of type I interferons (IFNs) still deserves attention as an alternative antiviral strategy. This study aimed to assess the therapeutic effectiveness of IFN-α in hospitalized patients with COVID-19-associated pneumonia. The prospective cohort study included 130 adult patients with coronavirus disease (COVID-19). A dose of 80,000 IU of IFN-α2b was administered daily intranasally for 10 days. Adding IFN-α2b to standard therapy reduces the length of the hospital stay by 3 days ( < 0.001). The level of CT-diagnosed lung injuries was reduced from 35% to 15% ( = 0.011) and CT injuries decreased from 50% to 15% ( = 0.017) by discharge. In the group of patients receiving IFN-α2b, the SpO2 index before and after treatment increased from 94 (92-96, Q -Q ) to 96 (96-98, Q -Q ) ( < 0.001), while the percentage of patients with normal saturation increased (from 33.9% to 74.6%, < 0.05), but the level of SpO2 decreased in the low (from 52.5% to 16.9%) and very low (from 13.6% to 8.5%) categories. The addition of IFN-α2b to standard therapy has a positive effect on the course of severe COVID-19.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms24086887